p.novotny
TL2 Regular · Prague, CZ
Lifter. Interested in preserving what I spent a decade building while losing fat.
Joined 3 June 2025 · last posted 4d
102Posts here
0Topics
1Solutions
138Likes received
213Likes given
18Badges
115Days visited
1.1kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #106 · Access › International · 24 Jul 2026 · 4 likes Travelling with a prescribed medicine is a documentation question and the requirements are published by the destination rather than the origin.
-
Restarting after a long gap: what the labelling implies Replied, post #37 · Practice › Dosing & titration · 21 Jul 2026 · 3 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #24 · Sourcing › Regulatory · 15 Jul 2026 · 0 likes That is the distinction I keep failing to hold on to. Written down now.
-
Follow-up: Signs of dehydration worth acting on Replied, post #25 · Safety › Adverse events · 15 Jul 2026 · 0 likes Severe gastrointestinal events: persistent vomiting, abdominal pain out of proportion, or signs of bowel obstruction warrant urgent evaluation. Mild nausea and…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #60 · Practice › Dosing & titration · 13 Jul 2026 · 8 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose. I…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #57 · Compounds › Retatrutide · 12 Jul 2026 · 2 likes On post #56 — agreed on the reasoning, with one qualification. Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #52 · Analytics › Impurities & related substances · 6 Jul 2026 · 13 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #111 · Evidence › Journal club · 5 Jul 2026 · 20 likes Worth separating two things that post #109 runs together. A definition problem is doing most of the work in this orforglipron phase 2 discussion. Once the term is…
-
Submitting a sample: the process end to end Replied, post #58 · Sourcing › Independent verification · 4 Jul 2026 · 29 likes Post #55 answers the question as asked. The question underneath it is different. It does not extend to lots nobody has seen, it is not a recommendation, and it says…
-
NHS criteria and how they are applied in practice Replied, post #8 · Regional › UK & Ireland · 21 Jun 2026 · 2 likes Picking up post #7: that is the part I would want checked first. Members outside these two jurisdictions reading this thread should note that none of it transfers,…
-
Racemisation and why it is invisible to a mass measurement Replied, post #123 · Analytics › Impurities & related substances · 15 Jun 2026 · 0 likes Deletion sequences (incomplete coupling during synthesis): lower in mass by one residue. Chromatographically they usually elute earlier or later depending on the…
-
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #7 · Devices › Syringes & needles · 13 Jun 2026 · 0 likes Second this, and I would have said it less carefully.